Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma

被引：0
|
作者：
Asai, Katsunori
Narita, Yoshitaka
Nagane, Motoo
Mishima, Kazuhiko
Terui, Yasuhito
Arakawa, Yoshiki
Yonezawa, Hajime
Fukuhara, Noriko
Sugiyama, Kazuhiko
Shinojima, Naoki
Aoi, Arata
Nishikawa, Ryo
机构：
[1] Osaka Int Canc Inst, Dept Neurosurg, Osaka, Japan
[2] Natl Canc Ctr, Dept Neurosurg & Neurooncol, Tokyo, Japan
[3] Kyorin Univ, Fac Med, Dept Neurosurg, Tokyo, Japan
[4] Saitama Med Univ Int Med Ctr, Dept Neurooncol Neurosurg, Saitama, Japan
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Hematol Oncol, Tokyo, Japan
[6] Kyoto Univ, Grad Sch Med, Dept Neurosurg, Kyoto, Japan
[7] Kagoshima Univ Hosp, Dept Neurosurg, Kagoshima, Japan
[8] Tohoku Univ, Grad Sch Med, Dept Hematol & Rheumatol, Sendai, Miyagi, Japan
[9] Hiroshima Univ Hosp, Dept Clin Oncol, Hiroshima, Japan
[10] Hiroshima Univ Hosp, Neurooncol Program, Hiroshima, Japan
[11] Kumamoto Univ Hosp, Dept Neurosurg, Kumamoto, Japan
[12] Ono Pharmaceut Co LTD, Dept Clin Dev, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7548
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Three-year follow-up analysis of phase 1/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
    Yonezawa, Hajime
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY ADVANCES, 2024, 6 (01)
  • [2] Post-Hoc Analysis of the Final, Three-Year Follow-up Results of a Phase I/II Study on Tirabrutinib (ONO-4059) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
    Fukuhara, Noriko
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2023, 142
  • [3] ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Mishima, Kazuhiko
    Narita, Yoshitaka
    Nagane, Motoo
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2020, 22 : 57 - 58
  • [4] Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2021, 23 (01) : 122 - 133
  • [5] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Okita, Yoshiko
    Kano-Fujiwara, Rieko
    Nakatsuka, Shin-Ichi
    Honma, Keiichiro
    Kinoshita, Manabu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [6] Quality of Life and Karnofsky Performance Status in Patients with Relapse or Refractory Primary Central Nervous System Lymphoma during Phase I/II Study of Tirabrutinib
    Terui, Yasuhito
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2021, 138
  • [7] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Yoshiko Okita
    Rieko Kano-Fujiwara
    Shin-Ichi Nakatsuka
    Keiichiro Honma
    Manabu Kinoshita
    Experimental Hematology & Oncology, 10
  • [8] Real World Evidence of Tirabrutinib As a Salvage Treatment in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: A Multicenter Study
    Liao, Chun-Kai
    Liu, Chia-Jen
    Tan, Tran-Der
    Wang, Ming-Chung
    Hsu, Ya-Ting
    Liu, Hung-Lin
    Wu, Shang-Ju
    Lu, Hsueh-Ju
    Du, Jeng-Shiun
    Gao, Wan-Jhen
    Tsai, Cheng-Chih
    BLOOD, 2024, 144 : 5137 - 5138
  • [9] Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib
    Arakawa, Yoshiki
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [10] Phase II trial of temsirolimus for relapsed/refractory primary central nervous system lymphoma (PCNSL)
    Kiewe, P.
    Martus, P.
    Thiel, E.
    Grobosch, T.
    Schlegel, U.
    Herlinger, U.
    Dreyling, M.
    Schmidt, C.
    Korfel, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 268 - 268
12345